TAK
Takeda Pharmaceutical Co Ltd ADRNYSE
Healthcare • Drug Manufacturers - Specialty & Generic
Updated 1 day ago
Coverage limited
$18.52-0.86%
Close Oct 13, 2026
- Market cap
- —
- 1 month
- -0.4%
- 3 months
- +12.6%
- 1 year
- +35.1%
- 52-week range
- $13.23$19.05
- Dividend, last 12 mo
- $0.3083 · 1.66% yield
- Last ex-date
- Mar 31, 2026 · $0.3083
- Dividend growth
- 2 years in a row
- Short interest
- 0.2% of float2.9M shares · settled Sep 30, 2026 · -30.6% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if TAK is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
49 top institutions tracked
as of 2026-Q2 (filed 2026-09-23)
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 29 days ago
Red flags: 0
Largest 13-F holders · Q2 2026
379 filers reported a long position in TAK for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Capital Research Global Investors | $309.3M | 19.3M | +1% |
| FMR LLC | $153.9M | 9.6M | +34.9% |
| MORGAN STANLEY | $112.1M | 7M | +8.1% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $97M | 6.1M | -5.8% |
| GOLDMAN SACHS GROUP INC | $82.2M | 5.1M | -8.8% |
| BRANDES INVESTMENT PARTNERS, LP | $72.8M | 4.5M | +2.5% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $59.8M | 3.7M | +19.8% |
| BlackRock, Inc. | $59.1M | 3.7M | +16.1% |
| RENAISSANCE TECHNOLOGIES LLC | $41.2M | 2.6M | -14.1% |
| Qube Research & Technologies Ltd | $35.4M | 2.2M | New |
Get the Full Analysis for TAK
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.